Back to Agenda
Session 6, Track C: Advancing Pharmacovigilance Through Artificial Intelligence: From Real-World Data to Practical Applications
Session Chair(s)
Daniel Greco, PharmD, MS, RPh
Associate Director of Patient Safety
Bristol-Myers Squibb Company, Canada
Nadia Latif, MS
Senior Manager, Pharmacovigilance
Ipsen Biopharmaceuticals Canada Inc., Canada
This session explores how artificial intelligence (AI) is transforming pharmacovigilance practice. It will showcase practical applications of AI that can enhance day-to-day routine activities in patient safety. The session will also highlight a use-case for patient identification. Attendees will gain insights into how AI can be applied to identify patient populations in real-world data and enhance post-market safety studies, using atopic dermatitis as a case study.
- Use of AI for Patient Identification in Safety Studies: Spotlight on Atopic Dermatitis Patient Prediction
Heather Ward, Pfizer - Practical Uses of AI
Indy Ahluwalia, ELIQUENT Life Sciences
Learning Objective :
At the conclusion of this session, participants should be able to:
- Identify practical, routine applications of AI that can enhance efficiency and decision-making in day-to-day patient safety activities
- Gain insights and knowledge of AI use in patient populations in real-world data and enhancing post-market safety studies
- Identify risks associated with the use of AI
Speaker(s)
Practical Uses of AI
Indy Ahluwalia
ELIQUENT Life Sciences, United Kingdom
Senior Managing Consultant
Use of AI for Patient Identification in Safety Studies: Spotlight on Atopic Dermatitis Patient Prediction
Heather Ward, PhD, MS
Pfizer, Canada
Director, Safety Surveillance Research
Have an account?